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Background: Microparticles (MPs) are membrane vesicles which are released from normal and malignant cells
following a process of budding and detachment from donor cells. MPs contain surface antigens, proteins and
genetic material and serve as vectors of intercellular communication. MPs comprise the major source of systemic
RNA including microRNA (miRNA), the aberrant expression of which appears to be associated with stage,
progression and spread of many cancers. Our previous study showed that MPs carry both transcripts and miRNAs
associated with the acquisition of multidrug resistance in cancer.
Results: Herein, we expand on our previous finding and demonstrate that MPs carry the transcripts of the
membrane vesiculation machinery (floppase and scramblase) as well as nucleic acids encoding the enzymes
essential for microRNA biogenesis (Drosha, Dicer and Argonaute). We also demonstrate using microarray miRNA
profiling analysis, the selective packaging of miRNAs (miR-1228*, miR-1246, miR-1308, miR-149*, miR-455-3p, miR-638
and miR-923) within the MP cargo upon release from the donor cells.
Conclusions: These miRNAs are present in both haematological and non-haematological cancer cells and are
involved in pathways implicated in cancer pathogenesis, membrane vesiculation and cascades regulated by ABC
transporters. Our recent findings reinforce our earlier reports that MP transfer ‘re-templates’ recipient cells so as to
reflect donor cell traits. We now demonstrate that this process is likely to occur via a process of selective packaging
of nucleic acid species, including regulatory nucleic acids upon MP vesiculation. These findings have significant
implications in understanding the cellular basis governing the intercellular acquisition and dominance of
deleterious traits in cancers.
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Extracellular membrane vesicles are important vehicles
of intercellular communication across numerous bio-
logical processes. MPs are typically defined by their size
(0.1-1 μm in diameter) [1], exposure of phosphatidylse-
rine (PS) and the expression of surface antigens origina-
ting from their donor cells [1-3].
MP vesiculation occurs as a cellular response to various
physiological conditions including; apoptosis, senescence,* Correspondence: mary.bebawy@uts.edu.au
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reproduction in any medium, provided the orcellular activation [4]; shearing stress and biochemical
triggers (such as cytokines and chemotherapeutics) [5]. In
the steady state the cell membrane is asymmetric in its
composition with phosphatidylcholine and sphingomyelin
located in the outer layer whereas phophatidylserine (PS)
and phosphatidylethanolamine (PE) present in the inner
layer. This asymmetric distribution in the membrane is
maintained by a group of two ATP-dependent enzymes
namely flippase, floppase as well as a bidirectional
ATP-independent scramblase [6-8]. Flippase specially
translocates PS and PE from the outside to the inside of
the bilayer membrane. Floppase transports phospholipids
and cholesterol from the inner to the outer leaflet.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phospholipids and probably works together with flippase.
Scramblase whose role is thought to be the transportation
of phospholipids between the two monolayers of the cell
membrane, is inactive in steady state [6-8]. Following
stress or under physiological conditions, an increase in
intracellular calcium, a subsequent loss of phospholipid
asymmetry following the inactivation of flippase and activa-
tion of floppase and scramblase, and disruption of the cyto-
skeletal apparatus occurs leading to MP vesiculation [6,7,9].
The released MPs are enriched in PS and PE exposed on
their outer surface. Consequently, MPs carry also cellular
proteins, second messengers, growth factors and genetic
material from their cells of origin [1,10] and comprise the
major source of RNA (ribosomal RNA (rRNA), messenger
RNA, (mRNA) and microRNA (miRNA) in systemic circu-
lation [11,12].
miRNAs are highly conserved, single-stranded non-
coding regulatory nucleic acids, typically 19–25 nucleo-
tides in length. These RNAs modulate the activity of
specific mRNA targets and serve as important regulators
of a wide range of pathophysiological processes [13].
miRNA synthesis begins in the nucleus by RNA poly-
merase II to form primary miRNA (pri-miRNA). Pri-
miRNA is processed by the ribonucleases, Drosha and
Dicer to generate mature miRNA. The single stranded
miRNA, in association with Argonaute 2, binds to com-
plementary sequences in the 3' untranslated region
(UTR) of target transcripts to regulate gene expression
either by translational repression, activation or degra-
dation of the mRNA transcript [1,14]. By targeting
several genes, miRNAs play important roles in normal
biological processes including cell proliferation, differen-
tiation, apoptotic cell death, stress resistance and phy-
siological metabolism [15,16]. Consequently, aberrant
expression of miRNAs has been associated with malig-
nancy, including; cancer stage, disease progression and
metastasic spread [17-19]. Furthermore, some miRNAs
have been shown to have oncogenic (such as mir-21, the
cluster mir-17–92, miR-155, miR-221 and miR-222) [20]
and tumour suppressive (such as let-7 in lung cancer
and miR-15/16 in leukaemia and prostate cancer) pro-
perties [21-23].
Given that MPs are emerging as an important source
of miRNA in the circulation in cancer patients [24-26] it
is feasible to propose a role for MP in the aberrant
miRNA levels displayed in oncogenesis and spread. This
reinforces the role that MPs play in cancer biology in-
cluding cell survival, invasion, metastasis and angiogen-
esis [27-31]. We recently discovered that MPs serve an
important function as mediators in the dissemination and
acquisition of multidrug resistance in cancer [32]. Specific-
ally, we have demonstrated that this occurs via the MP-
mediated transfer of functional resistance proteins, andnucleic acids including regulatory nucleic acids. In
addition, we also showed that the MP transfer ensured the
acquisition of the donor cell trait on to the recipient cells
[33].
We now expand on these findings and demonstrate
that MPs carry the transcripts encoding the membrane
vesiculation machinery (floppase and scramblase) and
the enzymes essential for microRNA biogenesis (Drosha,
Dicer and Argonaute). We also demonstrate the selective
packaging of miRNAs within MP cargo upon release
from the donor cells and propose that this process con-
tributes to the dissemination and acquisition of the
donor cell trait.Results
Microparticles incorporate transcripts encoding the
vesiculation machinery and microRNA biogenesis
enzymes
qRT-PCR analysis of leukaemic cells and their MPs show
that both the drug sensitive and resistant parental cells
as well as their MPs, carry the transcripts for the vesicu-
lation enzymes, floppase and scramblase (Figure 1A and
1B). Floppase is present at significantly higher levels in
the MPs relative to the donor cells (Figure 1A), whereas
scramblase, though present in all samples is present at
significantly lower levels in the resistant cells and their
MPs relative to the sensitive parental cells (Figure 1B).
MPs originating from VLB100 and CEM cells carry the
transcripts encoding the enzymes Drosha, Dicer and
Argonaute (Figure 1C, D and E), required for miRNA
biogenesis. Both the drug sensitive and the resistant cells
have significantly higher levels of the transcripts for
Drosha and Dicer relative to their MPs (Figure 1C and
D). Argonaute is also present in both the cells and their
MPs but with no significant differences in their levels
(Figure 1E).Presence of miRNAs and modulation of the recipient cell
miRNA profile following microparticle transfer
The quality of isolated RNAs was confirmed before subjecting
the samples to miRNA microarray analysis (Figure 2). After
normalization and transformation of the microarray data, the
box-whisker plot of probe signal intensity was used to assess
and confirm the quality of the microarray data (Figure 3A).
Among the 7,815 probe sets in themiRNAmicroarray (http://
www.affymetrix.com/support/technical/datasheets/miRNA_d
atasheet.pdf), 847 probes were annotated as human miRNAs.
The scatter plot of the signal intensities of these 847 human
miRNAs displayed a correlation betweenMPs and their donor
cells as well as between the acquired cells and the donor cells
(Figure 3B). The miRNA microarray data was validated by
qRT-PCR using the following selected miRNAs namely miR-
150,miR-210,miR-107 andmiR-125b (Figure 4).
Figure 1 MPs incorporate transcripts of vesiculation machinery and microRNA biogenesis enzymes. Quantitative RT-PCR showing the
levels of transcripts of vesiculation machinery (A) Floppase and (B) Scramblase and microRNA biogenesis enzymes (C) Drosha (D) Dicer and (E)
Argonaute 2 transcripts in CEM cells (white), CEMMP (light gray), VLB100 cells (dark gray) and VLBMP (black). Values are expressed as relative
expression with respect to the endogenous control gene, GAPDH. Data represent the mean± SEM of 3 independent experiments conducted in
duplicate *p< 0.05.
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transfer of drug resistance by MPs to recipient cells, the
miRNA expression profiles of MPs, drug sensitive recipi-
ent cells, acquired cells and donor cells were compared.
The hierarchical clustering analysis of the 847 human
miRNA uncovered selectively packaged miRNAs in the
MPs relative to the donor cells (Figure 5). Furthermore,
the acquired cells displayed a miRNA profile consistent
with the donor following MP transfer. The sensitive cells
were differential in their miRNA expression with respect
to their drug resistant counterparts. In total, 209 miR-
NAs in leukaemia and 215 in the breast cancer cells
were differentially expressed between the resistant donor
cells and their MPs (Figure 5). Also, 222 and 155 miR-
NAs were differentially expressed between the acquired
cells following MP transfer and the donor cells, in leu-
kaemia and breast cancer, respectively (Figure 5). 208
and 200 miRNAs were also found to be differentially
expressed between the drug sensitive and the resistant
cells, in leukaemia and breast cancer, respectively
(Figure 5). Of these, 195 miRNAs in leukaemia and 140
miRNAs in breast cancer were commonly identified be-
tween these two comparisons. The high level of similarityindicated the strong relationship between the MPs, the
acquired cells and the donor cells. In addition, hierarch-
ical clustering analysis of the 847 human miRNA ex-
pression profiles between all samples displayed common
trends across the two cancer cell lines and provides fur-
ther evidence of the tight correlation between the MPs,
acquired cells following MP transfer and the donor cells
(Figure 5).
To identify the most prominent miRNAs, linked with
the MP-mediated transfer of drug resistance trait to drug
sensitive cancer cells, selectively packaged and acquired
miRNAs having p-value less than 0.06 (p< 0.06) and
fold change more than 1.5 (FC> 1.5) were selected
(Figure 6). This comparison between leukaemia and
breast cancer cells showed that 17 miRNAs were identi-
fied as the important miRNAs selectively packaged into
MPs (Figure 7A). Likewise, across both cancers, 18 miR-
NAs were identified as significantly expressed miRNAs
in the acquired cells (Figure 7B).
The MPs have a higher expression of these identified
miRNAs relative to its donor cells, thereby being select-
ively packaged (Figure 7A), which are then transferred
to the recipient cells upon coculture (Figure 7B). The
Figure 2 RNA integrity of samples. RNA derived from (A) the drug sensitive-recipient cell (CEM), (B) drug-resistant VLB100 cells, (C) their isolated
MPs (VLBMP) and (D) the drug sensitive-recipient cells after MP transfer (CEM+ VLBMP) was analysed using Agilent RNA 6000 Nano kit by Agilent
2100 Bioanalyzer. The RIN value of the samples ranged between 6.2-9.2. Data is representative of a typical experiment.
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relative to their parental recipient cells (CEM and MCF-
7), following MP transfer. The expression levels in the
MP acquired recipient cells with respect to their parental
cells, is reflective of the donor cell trends (Figure 7B). Fi-
nally, 7 common miRNAs were identified as the most
essential (being codetected across both malignancies),
which may be important for the transfer of donor traits
via MPs (Figure 6). The 7 miRNAs, which were identi-
fied to be selectively packaged and acquired by recipient
cells across both cancers, include miR-1228*, miR-1246,
miR-1308, miR-149*, miR-455-3p, miR-638 and miR-923
(Table 1).
Microparticles selectively package miRNAs implicating
traits specific to membrane vesiculation, cancer etiology
and multidrug resistance on the target cell
The 1,571 unique predicted gene targets of the 7 miRNAs
were identified from miRBase (prediction score> 60) and
EMBL (p< 0.01). The gene target list was uploaded to
DAVID Bioinformatics Resources 6.7 web-based program
for functional annotation analysis. Significant biological
pathways (*EASE score< 0.05) were selected as the im-
portant pathways that may be involved in MP formation
and MDR trait transfer to recipient cells. The top 9 signifi-
cant correlated pathways (p< 0.05) include “melanogen-
esis”, “calcium signalling pathway”, “ABC transporters”,
“vascular smooth muscle contraction”, “hypertrophic car-
diomyopathy” “steroid biosynthesis”, “maturity onset dia-
betes of the young”, “regulation of actin cytoskeleton” and
“pathways in cancer” (Figure 8). Of these significant path-
ways identified for the miRNAs in this study, two were
related to MP vesiculation (“calcium signalling pathway”,
and “regulation of actin cytoskeleton”) and one to MDR(“ABC transporters”). Of all the target genes identified
for the miRNAs, the highest percentages (~2.5 %) of these
were observed to be related to the “pathways in cancer”.
In addition, of all the predicted pathways identified for the
miRNAs in this study, eight of them were related to malig-
nancies alone.
Discussion
This study demonstrates that MPs serve as vehicles for
intercellular communication and potentially as cancer
biomarkers through their discrete miRNA signatures.
RT-PCR analysis showed that MPs carry the transcripts
of their vesiculation machinery (floppase and scram-
blase) (Figure 1A and B) together with transcripts en-
coding miRNA biogenesis enzymes (Drosha, Dicer and
Argonaute) (Figure 1C, D and E). The presence of these
phospholipid enzymes (floppase and scramblase) may
help in intracellular vesicle trafficking either by inducing
membrane vesiculation or by providing an environment
favorable for binding of vesicle coat proteins [34]. This
finding suggests that MPs are self-sufficient and possess
the capacity to potentially induce vesiculation in the re-
cipient cell. Although, the presence of scramblase 1 and
3 in exosomes has been previously reported [20,35], to
our knowledge, this is the first demonstration of the
presence of transcripts encoding the vesiculation ma-
chinery in MPs. The presence of Drosha, Dicer and
Argonaute transcripts within the shed cargo potentially
implicates MPs as key intercellular regulators of miRNA
biogenesis in recipient cancer cell populations.
Affymetrix miRNA microarray was used to explore the
miRNA expression profiles of MPs and their donor cells
from both leukaemia and breast cancer cells in this
study (Figure 5). This data was validated using RT-PCR
Figure 3 Quality of data and gene expression signal correlation among identified miRNA. After normalization and transformation of the
microarray data (A) the box-whisker plot of probes signal intensity assessed and confirmed the microarray data quality. (B) The scatter plot of the
signal intensity of the 847 annotated human miRNAs showed that certain level of correlation was identified between the MPs (VLBMP or DXMP),
the acquired cells (CEM+ VLBMP or MCF-7+ DXMP) , the donor cells (VLB100 or DX) and the parental recipient cells (CEM and MCF-7).
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most miRNAs examined (miR-107, miR-125b and miR-
210) except for miR-150 (Figure 4). The basis of this dif-
ference in currently unknown and may be attributed to
the differences in assays. Our analysis showed that several
human miRNAs are selectively packaged into MPs. Upon
coculture with recipient cells, we observe an increase in
select miRNAs, inlcuding miR-1246, miR-1308, miR-
1228*, miR-149*, miR-638 and miR-923 (Figure 7).These
miRNAs displayed a 2-12-fold increase in expression
levels in the MPs relative to their donor cells (Figure 7A).
These observations are consistent with selective pack-
aging, which we have previously shown for miR-451 and
miR-326 in MPs shed from MDR resistant breast and
leukaemia cells [33]. In addition, our findings are consist-
ent with previous reports demonstrating that these samemiRNAs are also selectively packaged into exosomes
[24,36-38].
We also demonstrate that following MP transfer to reci-
pient breast cancer and leukaemia cells, the same miRNAs
were significantly increased in the acquired cells, with
levels ranging from 2-15-fold increase (Figure 7B). Once
again the expression level of the miRNAs in the MP com-
partment was directly correlated to the levels observed in
the acquired population following MP transfer (Figure 5).
In saying this however, we cannot exclude the possibility
that increased miRNA levels in the recipient cells are
caused by either/both direct or indirect MP-mediated
effects on the transcription of the miRNA. Interestingly,
the acquired population displayed miRNA expression
trends reflective of the donor cells (Figure 7B). This
demonstrates that the recipient cell reflects the donor
Figure 4 Validation of microarray data by qRT-PCR. By using qRT-PCR, miR-150, miR-210, miR-107 and miR-125b were analyzed in MPs, their
donor cells, the recipient cells before and after MP transfer across both leukaemia and breast cancer. Results depict similar trends in gene
expressions across samples by both qRT-PCR and microarray. qRT-PCR expression levels were normalized with respect to the endogenous control
gene, U6 whereas the microarray expression levels were normalized with respect to the human 5.8 s rRNA (gi555853). Data expressed as fold
differences represents the mean± SEM o f 2 independent experiments conducted in triplicates * p< 0.05.
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are consistent with our previous report where we have
shown the “re-templating” of recipient cells to reflect
donor cell traits following MP-mediated transfer of MDR
transporter transcripts [33].
The miRNAs identified in our study play crucial roles
in cancer cell biology. Using the miRDB target predic-
tion program [39], NKIRAS1, which is a NFKB inhibitor
was identified as one of the targets of miR-1308. Nuclear
factor kappa B (NFκB) is a family of transcription factors
that play important roles in regulating cell differenti-
ation, proliferation, immune response and blocking
apoptosis [40,41]. This family of transcription factors
have been reported to chemosensitize P-gp overexpres-
sing cancer cells [42]. This miRNA has also been shown
to be upregulated in cancerous tissues and also in the
more aggressive inflammatory breast cancer (IBC) in
comparison to the non-IBC tissues [43,44]. Similarly,
miR-1246 targets the NKF3 kinase family member gene,
SGK269 (miRDB database). NKF3 or PEAK1 promotes
anchorage independent growth and tumour progression
in pancreatic cancer cells transplanted in mice [45].
miR-149* is known to induce apoptosis by the direct
inhibition of Akt1 and E2F1 in neuroblastoma cells
[46]. Akt is the key kinase of the signal pathway, which
mediates the regulation of divergent cellular processesincluding apoptosis, proliferation, differentiation and
metabolism [47].
miR-638 has been found to be consistently, highly
expressed in human plasma and its presence in the
plasma may be physiologically necessary [48]. As such,
the ratio of miR-92a/miR-638 in blood is associated with
diagnosis in acute leukaemia patients [48]. Gene targets
of miR-638, cyclin G2 and transcription elongation regu-
lator 1-like factor (miRDB database), were involved in
p53 and platelet-derived growth factor (PDGF) signalling
pathways [49]. miR-638 was one of the downregulated
miRNAs in colorectal liver metastases with respect to
the adjacent liver tissues that have the potential to serve
as a prognostic and predictive marker of colorectal liver
metastases [50]. Likewise, miR-1228* has been previously
shown to be highly expressed in malignant mesotheli-
oma tumour samples compared to normal samples [51].
The role of the miRNAs and their targeted pathways in
the cells examined in this study are currently unknown. It is
feasible that the same miRNAs may serve similar functions
in these cells as is the case in the other reported cancers.
However, the pathway analysis of the predicted targets of the
7 identified miRNAs in this study showed the maximum
percentage of target genes to be significantly related to
“pathways in cancer” and at least seven other pathways as
well that were cancer related (Figure 8). The malignancy-
Figure 5 miRNA expression profiles of MPs, their donor drug
resistant cells, the recipient drug sensitive cells and the
cocultures after MP transfer. Hierarchical clustering analysis of the
847 human miRNA signal intensities identified by the Affymetric
miRNA microarray detectable in the drug resistant MPs (VLBMP and
DXMP), their donor cells (VLB100 and DX) and the drug sensitive
recipient cells before (CEM and MCF-7) and after MP transfer
(CEM+ VLBMP and MCF-7 +DXMP) across both leukaemia and
breast cancer samples. This shows evidence of the tight correlation
between the MPs, cocultured cells and MP donor cells. Vertical bars
represent the samples and the horizontal bars represent the miRNA
genes. Green bars reflect downregulated genes and red bars
upregulated genes.
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as potential biomarker in the treatment of cancer.
Chemotherapy comprises the major therapeutic strat-
egy for clinical cancer treatment. However, chemother-
apy fails to eliminate all tumour cells because of
intrinsic or acquired drug resistance, which is the most
common cause of tumour recurrence [52,53]. The role
of miRNAs in the regulation of resistance mediated by
multidrug transporters has only been examined recently
[33]. Interestingly, we found that some of the signifi-
cantly expressed miRNAs (like miR-455-3p) identified
in this study target the multidrug resistant protein,P-glycoprotein (P-gp). For example, miRDB target pre-
diction shows MDR member 1 or (P-gp) and HIF1AN
(hypoxia-inducible factor 1, alpha subunit inhibitor) as
miR-455-3p targets. HIF-1 alpha has been shown to induce
MDR in hepatocellular carcinoma cell line [54]. In this
study, the microarray analysis showed that the resistant leu-
kaemia cell line has a lower expression level of this miRNA
relative to its drug sensitive cells, which is consistent with
its overexpression of P-gp. In the acquired cells we
observed a suppression of miR-455-3p implicating poten-
tially increased P-gp levels after MP transfer. Hence, our
previous observations of P-gp protein transfer in the drug
sensitive recipient cells after MP coculture [32] may be due
to the transfer of these regulatory miRNAs together with
protein via the MP cargo. In breast cancer, the overexpres-
sion of miR-923 was shown to be upregulated in the Taxol
resistant cancer cells relative to the normal cells [55].
Other than pathways related to malignancies and
MP vesiculation, “ABC transporters” was identified
as a significant biological pathway with the highest
percentages of the identified miRNA target genes. Pre-
vious studies have also reported on the role of miR-
NAs involved in MDR in cancer. These include miR-
27a and miR-451, whose expressions were shown to
induce MDR1/P-gp expression in resistant human
ovarian cancer cells [56]. The overexpression of MRP1
and miR-326 levels was inversely related in breast can-
cer tissues and leukaemia [33,57]. Recently, miR-345
and miR-7 have shown to target MRP1 in MDR breast
cancer cells relative to parental cells [58]. Apart from
MDR, the ABC transporter, ABCA1 has also been
shown to possess floppase activity and is related to
MP production [59]. In addition, of the significant
predicted pathways identified for the miRNAs in this
study, two of them namely: “calcium signalling path-
way” and “regulation of actin cytoskeleton” were
related to MP vesiculation (Figure 8). This suggests
that MPs not only carry the enzymes for its release
but also carry miRNAs and genes which may be po-
tentially involved in its production and release.
Our study gives an implication of the role miRNAs
contained within the MP cargo may play in contribut-
ing to the emergence of MDR and in regulating trans-
porter expression in recipient cancer cells. Previous
studies have shown miRNA transferred by other ves-
icular bodies like microvesicles to be functional in the
recipient cells [60,61]. However, the functional role of
the identified miRNAs in this study needs further ex-
ploration to have any clinical relevance.
Conclusions
In conclusion, this study reveals miRNAs not only as
oncogenic or tumour suppressive, but also highlights
the potential role of these molecules as a potential class
Figure 6 Identification of significantly expressed miRNA by comparison profiles. The Venn diagrams depicts 51 (leukaemia) and 78 (breast
cancer) significantly and differentially expressed miRNA genes that were selectively packaged, whereas 48 (leukaemia) and 94 (breast cancer)
significantly and differentially expressed miRNA that were acquired via MP transfer. Finally, 7 of the miRNA genes were co-detected across both
cancers that were selectively packaged in the MP and were acquired by the recipient cells, after MP transfer. Significant miRNA genes having
p< 0.06 were selected for analysis and from which those having fold change> 1.5 were identified as differentially expressed across both cancers.
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and non-haematological malignancies. The miRNAs
transferred by MPs also play an important role in the
regulation of biological processes involved in anticancer
drug resistance. Indeed, the detection of circulating
tumour-derived transcripts from melanoma, breast and
lung cancer patients has identified MPs as potential mar-
kers of diagnostic and prognostic significance [26]. Thus,
miRNA profiling has the potential to serve as a non-
invasive approach to probe for the presence of deleterious
cancer traits clinically.Figure 7 MPs selectively package miRNA genes. Hierarchical clustering
DX) versus their MPs (VLBMP or DXMP) show clear differences in the expre
are selectively packaged into MPs. (B) Recipient cells resemble the donor a
breast cancer sensitive recipient cells (CEM or MCF-7), resistant donor cells
(CEM+ VLBMP or MCF-7 +DXMP) shows that the recipient miRNA gene exp
across both cells types. Heatmaps show the signal intensities of the co-det
similar expression levels in the coculture with respect to its donor cells. The
bars reflect downregulated genes and red bars upregulated genes.Methods
Cell Lines
Two cell lines were used for these studies. The first cell
line included the drug-sensitive human acute lympho-
blastic leukaemia cell line CCRF-CEM (designated CEM
for simplicity), and its MDR variant VLB100. The second
included the drug-sensitive human breast adenocarcinoma
cell line MCF-7, and its MDR variant MCF-7/DX (desig-
nated as DX for simplicity). These cells were kind gifts
from Dr Rosanna Supino (Istituto Nazionale per lo Studio
e la Cura dei Tumouri, Milan, Italy) and Dr Suzanne M.analysis of leukaemia and breast cancer (A) resistant cells (VLB100 or
ssion of genes between the cells and the MPs depicting some miRNAs
fter MP co-incubation. Hierarchical clustering analysis of leukaemia and
(VLB100 or DX) versus the recipient cells cocultured with MPs
ression trends follow that of the donor cells after MP co-incubation
ected miRNAs which have higher expression levels in the MPs whereas
identified miRNAs have a fold change> 1.5 and p-value< 0.06. Green
Table 1 The list of identified miRNAs with their characteristics
miRNA name miRBase sanger
accession number




hsa-miR-149-star MIMAT0004609 5' - agggagggacgggggcugugc - 3' 21 MI0000478 2q37.3
hsa-miR-455-3p MIMAT0004784 5' - gcaguccaugggcauauacac - 3' 21 MI0003513 9q32
hsa-miR-638 MIMAT0003308 5' - agggaucgcgggcggguggcggccu - 3' 25 MI0003653 19p13.2
hsa-miR-923 MIMAT0004973 5' - gucagcggaggaaaagaaacu - 3' 23 MI0005715 Fragment of the
28 S rRNA
hsa-miR-1228-star MIMAT0005583 5’- ucacaccugccucgcccccc -3’ 20 MI0006318 12
hsa-miR-1246 MIMAT0005898 5’- aauggauuuuuggagcagg -3’ 19 MI0006381 2q31.1
hsa-miR-1308 MIMAT0005947 5’- gcaugggugguucagugg -3’ 18 MI0006441 Fragment of
a tRNA
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these cell lines have been validated earlier by our group as
an appropriate model for the study of P-gp-mediated
MDR in vitro [32,62,63]. All cell lines were cultured in
RPMI 1640 (Invitrogen Australia, VIC, Australia) contain-
ing 10% FCS (Invitrogen, Australia) and maintained under
a humidified incubator at 37°C in an atmosphere of 5%
CO2.Figure 8 Selected miRNAs have common biological pathways. The co
targets for the seven co-detected miRNA genes by DAVID Bioinformatics R
were plotted against the pathways they regulate (x-axis) with increasing p-
with p-value< 0.05. The green bars indicate the pathways associated with
selected as the important pathways. *Ease Score Threshold (Maximum Prob
for gene-enrichment analysis. p-value <0.05 represents strong enrichmentMP harvesting and identification
MPs were isolated from confluent CEM, VLB100 and DX
cells by differential centrifugation, as previously described
[32,33]. The MPs were designated as CEMMP, VLBMP
and DXMP for simplicity. Briefly, culture supernatants
were collected and centrifuged at 500 g for 5 min to pellet
whole cells. The collected supernatant was re-centrifuged
at 15,000 g for 1 h at 15°C to pellet the MPs. The finalmmon biological pathways were identified with the list of predicted
esources. The percentages of the total identified target genes (y-axis)
value. The pathways in red bars indicate most significant pathways
malignancies. Significant biological pathways (*EASE score< 0.05) were
ability): The threshold of EASE Score, a modified Fisher Exact p-value,
in the annotation categories.
Table 2 The list of sequences of primers used for real-
time RT-PCR experiments
Primers Sequences
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and centrifuged at 2000 g for 1 min to remove debris. The
clear MP suspension was further centrifuged at 18,000 g
for 30 min at 15°C to pellet MPs. Validation of the isolated
MP pellet was performed using flow cytometric analysis
(FCM) (Cytomics FC500 MPL, Beckman Coulter) after
FITC-annexin V (Beckman Coulter, NSW, Australia) stain-
ing as previously described [32]. Total protein content of
MPs was determined using the Quant-iT™ protein assay as
per the manufacturer’s instructions (Invitrogen Australia).Reverse: 5’-TTCAAGCAATTCTCGCACAG-3’
Drosha Forward: 5’-TGCAACTGGTAGCCACAGAG-3’
Reverse: 5’-ACACTGCTGAAGCTGGGATT-3’







miR-210 5'-CTGTGCGTGTGACAGCGGCTGA-3'MP transfer experiment and isolation of mRNA
In a 96-well U bottom culture plates, 180 μg of VLBMP or
DXMP was cocultured with 1 x 105 CEM or MCF-7 cells,
respectively, for 4 h in total of 200 μL complete RPMI cul-
ture medium at 37°C and 5% CO2. Unbound MPs were
removed by washing with PBS and centrifuging at 500 g
for 5 min at 25°C after 4 h. The cocultured samples were
designated as CEM+VLBMP and MCF-7+DXMP for
simplicity and were referred to as the “acquired” cells.
Total RNA was extracted and pooled using TrizolW
Reagent (Molecular Research Center, Inc, OH, U.S.A.) as
per manufacturer’s recommendations from (i) the paren-
tal drug sensitive CEM or MCF-7 cells, (ii) the MDR
strain VLB100 or DX cells, (iii) VLBMP or DXMP, and
(iv) the cocultured samples CEM+VLBMP or MCF-7
+DXMP from duplicate experiments.Gene expression analysis of MP vesiculation and miRNA
biogenesis enzymes
Quantitative real-time polymerase chain reaction (qRT-
PCR) was used to assess the presence of scramblase and
floppase RNA transcripts (involved in MP budding), as
well as Argonaute, Dicer and Drosha RNA transcripts
(involved in miRNA biogenesis) in isolated MPs. Briefly,
cDNA was synthesized using the Advantage RT-for-PCR
Kit (Clontech Laboratories, Inc., Mountain View, CA).
The specific primers against the target genes were used
with GAPDH as the housekeeping primer (Sigma-Aldrich,
St Louis, MO, USA) (Table 2). Reactions were carried out
at the volume of 10 μL using 2× SYBR Green Premix
ExTaq (Takara Bio Inc., Shiga, Japan) with 10 pmole of tar-
get specific primer pairs and the amplification were per-
formed on the LightCycler 2.0 (Roche, NSW, Australia).
The thermal profile for the qRT-PCR was 95°C for 5 min
followed by 45 cycles of 95°C for 5 sec, 55°C for 10 sec,
and 72°C for 15 sec. The Ct data of each sample was com-
pared with the housekeeping gene to obtain the ΔCt using
the following formula: ΔCt = target gene Ct−housekeep-
ing gene Ct. The relative expression level was calculated
using ΔΔCt = 2-ΔCt and expressed as fold difference from
the experimental control ([ΔΔCt of sample  ΔΔCt of
drug-sensitive cells] x 1) as arbitrary units (a.u.).Analysis of RNA integrity and Affymetrix miRNA Arrays
Total RNA integrity was analysed using the Agilent RNA
6000 Nano kit (Agilent Technologies Inc., Santa Clara,
CA) and the result was analysed by Agilent 2100 Bioanaly-
zer (Agilent Technologies Inc.) as per the manufacturer’s
recommendations; the RNA integrity number (RIN) of 10
represents the highest RNA integrity with minimal degrad-
ation and score of 1 is the lowest integrity [64]. Nanodrop-
1000 spectrophotometer (Nanodrop technologies, DE,
USA) was used for the quantification of RNA and 500 ng
of RNA from each sample was used for miRNA microarray
analysis. RNA labelling, hybridization (Affymetrix™ Fluidics
Station 450), scanning (GeneChipW Scanner 3000 7 G) and
raw data acquisition of the Affymetrix GeneChip W miRNA
Array (P/N 901326) were performed by Australian
Genome Research Facility Ltd, VIC, Australia following a
standard procedure from Affymetrix™ (Santa Clara,CA).
miRNA Microarray analysis
Data processing
Affymetrix “CEL” and “CHP” data files of each sample were
processed with AffymetrixTM miRNA QCTool software and
following the guided workflow as described in the user man-
ual (http://www.affymetrix.com/support/technical/manuals.
affx). Briefly, the signal intensities data was extracted from
data files and probes level intensity data were obtained using
Wilcoxon-Rank Sum test, followed by background adjust-
ment based on the GC content of ‘anti-genomic’ probes,
quantile normalization, addition of a small constant (value
16) to avoid negative signal after background-GC correction,
and finally applying median summarization to all probe set
in each sample. Probe intensities data presented are all log2
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after Wilcoxon-Rank Sum test. All microarray data dis-
cussed in this manuscript have been deposited in NCBI's
Gene Expression Omnibus and are accessible through




Data was filtered to include only annotated as Homo
sapiens and miRNA, and probes with the p-value less
than 0.06 (p< 0.06) were selected as a significant for fur-
ther analysis. To identify those miRNAs that were corre-
lated to drug resistance and its transfer from the donor
to recipient cells by MPs, expression profiles of (i) MP
donor cells (VLB100 or DX), (ii) isolated MPs (VLBMP
or DXMP), and (iii) MP cocultured with drug sensitive
cells (CEM+VLBMP or MCF-7+DXMP) were com-
pared, and miRNAs with fold change more than 1.5
(FC> 1.5) were identified.
Hierarchical clustering and targeting pathway analysis
‘Cluster 3.0’ program [65] was used for hierarchical clus-
tering analysis, where selected miRNAs were clustered
by centroid linkage using Euclidean distance, and
depicted result was generated using ‘Java Tree View’ pro-
gram [66]. Furthermore, a complete list of predicted
gene targets on the selected miRNAs was downloaded
from miRBase (Release version 16) (http://www.mirbase.
org), miRDB ((http://www.mirdb.org) and the EMBL
Nucleotide Sequence Database (http://www.ebi.ac.uk/
embl/). The target genes for individual miRNAs with a
score> 60 (miRBase) or with p-value< 0.01 (EMBL)
were selected and uploaded to the online DAVID Bio-
informatics Resources 6.7 program (http://david.abcc.
ncifcrf.gov/) for their functional annotation clustering
analysis. The biological pathways and gene regulation by
the selected miRNAs were identified.
Microarray gene expression validation by qRT-PCR
Total RNA from isolated MPs, acquired cells and whole
cells were extracted as described above. cDNA for
miRNA was synthesized using the NCode miRNA First
Strand cDNA Module kit (Invitrogen Australia) on the
GeneAmp PCRSystem 9700 (Applied Biosystems). miR-
150, miR-210, miR-107 and miR-125b miRNA specific
primers (10 pmole/reaction) were used for PCR for the
detection of miRNAs using miR-U6 as the housekeeping
primer (all primers were from Sigma-Aldrich) (Table 2).
SYBR Green qRT-PCR amplifications were performed
on the MastercyclerW ep realplex (Eppendorf, NY, USA).
Reactions were carried out in a 20 μL volume containing
10 μL of 2 × SYBR Green Premix ExTaq (Takara). The
thermal profile for the qRT-PCR was 91°C for 5 minfollowed by 45 cycles of 91°C for 15 sec, 60°C for 30 sec,
followed by melting curve detection. The Ct data of each
sample was collected automatically and data expressed
as described above.
Statistical analysis
A one-way analysis of variance (ANOVA) was used for
comparison and statistical analysis between the sample
populations and the control drug-sensitive cell population
using the Graph Pad Prism software. p-values less than
0.05 were accepted as statistically significant.
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